| Jan 4th 2010 | 200,000 Orion A-shares converted into B-shares |
| Jan 19th 2010 | ORION CORPORATION: Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2010 AGM of Orion Corporation, 19 Jan 2010 |
| Jan 20th 2010 | Annual Summary of Stock Exchange Releases published in 2009 |
| Feb 1st 2010 | Orion invites analysts and media to Financial Statement Release conference on 9 February 2010 |
| Feb 9th 2010 | Orion Group Financial Statement Release of 2009 |
| Feb 9th 2010 | Notice to the Annual General Meeting of Orion Corporation |
| Feb 18th 2010 | The Board of Directors of Orion Corporation decided on an incentive plan for key persons |
| Mar 1st 2010 | Orion Corporation: Transfer of 65,606 own B-shares on 1 March 2010 |
| Mar 2nd 2010 | Orion Group Annual Report 2009 published |
| Mar 11th 2010 | Orion Corporation: Member of the Board of Directors of Orion Corporation Leena Palotie passed away |
| Mar 24th 2010 | Orion Corporation: Decisions by the AGM on 24 March 2010 |
| Mar 24th 2010 | Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of Directors. Compositions of Board committees |
| Apr 1st 2010 | Orion comments on FDA release on Stalevo |
| Apr 8th 2010 | Amendment of Section 12 of Articles of Association entered in the Trade Register |
| Apr 15th 2010 | Orion invites analysts and media to Q1 news conference on Tuesday 27 April 2010 |
| Apr 20th 2010 | Dexmedetomidine Phase III program completed with positive results |
| Apr 27th 2010 | Orion Group Interim Report January-March 2010 |
| Apr 30th 2010 | 1,700,000 Orion A-shares converted into B-shares |
| May 18th 2010 | Change in Orion Group Executive Management Board as of 1 Oct 2010 |
| May 18th 2010 | Decision by the Board of Directors to repurchase own shares |
| Jun 1st 2010 | 1,100,000 Orion A-shares converted into B-shares |
| Jun 14th 2010 | Orion upgrades full-year outlook for 2010 |
| Jun 15th 2010 | Composition of R&D Committee as of 15 June 2010 |
| Jun 17th 2010 | 20,138 Orion A-shares converted into B-shares |
| Jun 22nd 2010 | Orion and Sun settle patent dispute |
| Jul 19th 2010 | Orion invites analysts and media to Q2 news conference on Tuesday 10 August 2010 |
| Aug 10th 2010 | Orion Corporation's publication schedules for financial reporting in 2011 |
| Aug 10th 2010 | Orion Group Interim Report January-June 2010 |
| Aug 13th 2010 | 435,019 Orion A-shares converted into B-shares |
| Aug 20th 2010 | Orion comments on today's FDA release on safety review of Stalevo® |
| Sep 1st 2010 | Orion: Change in the holding of own shares |
| Sep 24th 2010 | Change in Orion Group Executive Management Board as of 1 Jan 2011 |
| Oct 11th 2010 | Orion invites analysts and media to Q3 news conference on Tuesday 26 October 2010 |
| Oct 15th 2010 | Disclosure Under Chapter 2 Section 9 |
| Oct 20th 2010 | European Medicines Agency has initiated the review of Orion's dexmedetomidine marketing authorisation application |
| Oct 26th 2010 | Orion Group Interim Report January-September 2010 |
| Nov 1st 2010 | Composition of the Nomination Committee of Orion Corporation |
| Nov 12th 2010 | 321,946 Orion A-shares converted into B-shares |
| Dec 15th 2010 | Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Comtan® (entacapone) in the United States |
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.